A study of JAK2 (V617F) gene mutation in patients with chronic myeloproliferative disorders

Noor Hamidah Hussin, N. R. Farisah, A. B. Azlinda, F. L. Wong, Srijit Das, S. A W Fadillah, O. Ainoon

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background and Aims: Chronic myeloproliferative diseases (MPDs) are heterogenous group of haematological malignant disorders. It is now a well recognized fact that the JAK2 (V617F) mutation occurs in majority of the patients with polycythaemia vera (PV) and half of those with myelofibrosis and essential thrombocythaemia. The presence of JAK2 (V617F) mutation is considered an important criterion for the exclusion of secondary/reactive from clonal disorders. In the present uni-institutional study, we analyzed the JAK2 (V617F) mutation status in the ethnic Malay and Chinese patients who were diagnosed as MPDs. Materials and Methods: The study was performed on known cases of chronic MPDs either at diagnosis or during the follow-up. A total of 45 cases were studied with informed consent. The allele specific PCR, ARMS-PCR and RQ-PCR methods were used. Results: The frequency of the JAK2 (V617F) mutation varied between the MPD subtypes, with the mutation being most frequent in PV (95.8%) and 39% showed homozygous mutant allele. The mutation was detected in 52.9% cases of ET, of which 36.4% were homozygous for the mutant allele and 1 case of MF was homozygous for the mutant allele.. Conclusion: Screening for the mutation in all cases suspected of chronic MPD could be beneficial in differentiating patients with reactive erthrocytosis or thrombocytosis from the true clonal MPDs especially polycythaemia vera.

Original languageEnglish
Pages (from-to)109-113
Number of pages5
JournalClinica Terapeutica
Volume163
Issue number2
Publication statusPublished - 2012

Fingerprint

Myeloproliferative Disorders
Mutation
Polycythemia Vera
Genes
Alleles
Chronic Disease
Polymerase Chain Reaction
Adjustment Disorders
Essential Thrombocythemia
Thrombocytosis
Primary Myelofibrosis
Informed Consent

Keywords

  • Chronic myeloproliferative disease
  • JAK2 (V617F) mutation
  • Polycythaemia vera
  • Polymerase chain reaction
  • Thrombocythaemia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hussin, N. H., Farisah, N. R., Azlinda, A. B., Wong, F. L., Das, S., Fadillah, S. A. W., & Ainoon, O. (2012). A study of JAK2 (V617F) gene mutation in patients with chronic myeloproliferative disorders. Clinica Terapeutica, 163(2), 109-113.

A study of JAK2 (V617F) gene mutation in patients with chronic myeloproliferative disorders. / Hussin, Noor Hamidah; Farisah, N. R.; Azlinda, A. B.; Wong, F. L.; Das, Srijit; Fadillah, S. A W; Ainoon, O.

In: Clinica Terapeutica, Vol. 163, No. 2, 2012, p. 109-113.

Research output: Contribution to journalArticle

Hussin, NH, Farisah, NR, Azlinda, AB, Wong, FL, Das, S, Fadillah, SAW & Ainoon, O 2012, 'A study of JAK2 (V617F) gene mutation in patients with chronic myeloproliferative disorders', Clinica Terapeutica, vol. 163, no. 2, pp. 109-113.
Hussin, Noor Hamidah ; Farisah, N. R. ; Azlinda, A. B. ; Wong, F. L. ; Das, Srijit ; Fadillah, S. A W ; Ainoon, O. / A study of JAK2 (V617F) gene mutation in patients with chronic myeloproliferative disorders. In: Clinica Terapeutica. 2012 ; Vol. 163, No. 2. pp. 109-113.
@article{2b7f8b927d75486eaa0e6b9d581eef45,
title = "A study of JAK2 (V617F) gene mutation in patients with chronic myeloproliferative disorders",
abstract = "Background and Aims: Chronic myeloproliferative diseases (MPDs) are heterogenous group of haematological malignant disorders. It is now a well recognized fact that the JAK2 (V617F) mutation occurs in majority of the patients with polycythaemia vera (PV) and half of those with myelofibrosis and essential thrombocythaemia. The presence of JAK2 (V617F) mutation is considered an important criterion for the exclusion of secondary/reactive from clonal disorders. In the present uni-institutional study, we analyzed the JAK2 (V617F) mutation status in the ethnic Malay and Chinese patients who were diagnosed as MPDs. Materials and Methods: The study was performed on known cases of chronic MPDs either at diagnosis or during the follow-up. A total of 45 cases were studied with informed consent. The allele specific PCR, ARMS-PCR and RQ-PCR methods were used. Results: The frequency of the JAK2 (V617F) mutation varied between the MPD subtypes, with the mutation being most frequent in PV (95.8{\%}) and 39{\%} showed homozygous mutant allele. The mutation was detected in 52.9{\%} cases of ET, of which 36.4{\%} were homozygous for the mutant allele and 1 case of MF was homozygous for the mutant allele.. Conclusion: Screening for the mutation in all cases suspected of chronic MPD could be beneficial in differentiating patients with reactive erthrocytosis or thrombocytosis from the true clonal MPDs especially polycythaemia vera.",
keywords = "Chronic myeloproliferative disease, JAK2 (V617F) mutation, Polycythaemia vera, Polymerase chain reaction, Thrombocythaemia",
author = "Hussin, {Noor Hamidah} and Farisah, {N. R.} and Azlinda, {A. B.} and Wong, {F. L.} and Srijit Das and Fadillah, {S. A W} and O. Ainoon",
year = "2012",
language = "English",
volume = "163",
pages = "109--113",
journal = "Clinica Terapeutica",
issn = "0009-9074",
publisher = "Societa Editrice Universo",
number = "2",

}

TY - JOUR

T1 - A study of JAK2 (V617F) gene mutation in patients with chronic myeloproliferative disorders

AU - Hussin, Noor Hamidah

AU - Farisah, N. R.

AU - Azlinda, A. B.

AU - Wong, F. L.

AU - Das, Srijit

AU - Fadillah, S. A W

AU - Ainoon, O.

PY - 2012

Y1 - 2012

N2 - Background and Aims: Chronic myeloproliferative diseases (MPDs) are heterogenous group of haematological malignant disorders. It is now a well recognized fact that the JAK2 (V617F) mutation occurs in majority of the patients with polycythaemia vera (PV) and half of those with myelofibrosis and essential thrombocythaemia. The presence of JAK2 (V617F) mutation is considered an important criterion for the exclusion of secondary/reactive from clonal disorders. In the present uni-institutional study, we analyzed the JAK2 (V617F) mutation status in the ethnic Malay and Chinese patients who were diagnosed as MPDs. Materials and Methods: The study was performed on known cases of chronic MPDs either at diagnosis or during the follow-up. A total of 45 cases were studied with informed consent. The allele specific PCR, ARMS-PCR and RQ-PCR methods were used. Results: The frequency of the JAK2 (V617F) mutation varied between the MPD subtypes, with the mutation being most frequent in PV (95.8%) and 39% showed homozygous mutant allele. The mutation was detected in 52.9% cases of ET, of which 36.4% were homozygous for the mutant allele and 1 case of MF was homozygous for the mutant allele.. Conclusion: Screening for the mutation in all cases suspected of chronic MPD could be beneficial in differentiating patients with reactive erthrocytosis or thrombocytosis from the true clonal MPDs especially polycythaemia vera.

AB - Background and Aims: Chronic myeloproliferative diseases (MPDs) are heterogenous group of haematological malignant disorders. It is now a well recognized fact that the JAK2 (V617F) mutation occurs in majority of the patients with polycythaemia vera (PV) and half of those with myelofibrosis and essential thrombocythaemia. The presence of JAK2 (V617F) mutation is considered an important criterion for the exclusion of secondary/reactive from clonal disorders. In the present uni-institutional study, we analyzed the JAK2 (V617F) mutation status in the ethnic Malay and Chinese patients who were diagnosed as MPDs. Materials and Methods: The study was performed on known cases of chronic MPDs either at diagnosis or during the follow-up. A total of 45 cases were studied with informed consent. The allele specific PCR, ARMS-PCR and RQ-PCR methods were used. Results: The frequency of the JAK2 (V617F) mutation varied between the MPD subtypes, with the mutation being most frequent in PV (95.8%) and 39% showed homozygous mutant allele. The mutation was detected in 52.9% cases of ET, of which 36.4% were homozygous for the mutant allele and 1 case of MF was homozygous for the mutant allele.. Conclusion: Screening for the mutation in all cases suspected of chronic MPD could be beneficial in differentiating patients with reactive erthrocytosis or thrombocytosis from the true clonal MPDs especially polycythaemia vera.

KW - Chronic myeloproliferative disease

KW - JAK2 (V617F) mutation

KW - Polycythaemia vera

KW - Polymerase chain reaction

KW - Thrombocythaemia

UR - http://www.scopus.com/inward/record.url?scp=84863993306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863993306&partnerID=8YFLogxK

M3 - Article

VL - 163

SP - 109

EP - 113

JO - Clinica Terapeutica

JF - Clinica Terapeutica

SN - 0009-9074

IS - 2

ER -